Albireo Pharma Inc Quick Ratio (ALBO) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Albireo Pharma inc   (NASDAQ: ALBO)

Albireo Pharma Inc 's Quick Ratio

ALBO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Albireo Pharma Inc 's Cash & cash equivalent grew by 22.93 % in the Q3 2022 sequentially, while Current Liabilities decreased, this led to improvement in Albireo Pharma Inc 's Quick Ratio to 5.88, Quick Ratio remained below Albireo Pharma inc average.

Within Major Pharmaceutical Preparations industry 249 other companies have achieved higher Quick Ratio than Albireo Pharma Inc in third quarter 2022. While Quick Ratio total ranking in the third quarter 2022 has deteriorated compared to the prior quarter from 708 to 813.

Explain Quick Ratio?
How much Cash & cash equivalents ALBO´s has?
What are ALBO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALBO Quick Ratio (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3
Y / Y Current Liabilities Change 14.09 % 61.49 % 41.85 % 79.36 % 56.16 %
Y / Y Cash & cash equivalent Change -15.28 % -2.85 % -0.2 % -1.26 % -5.77 %
Quick Ratio MRQ 5.88 4.15 6.88 5.47 7.92
ALBO's Total Ranking # 813 # 708 # 714 # 335 # 753
Seq. Current Liabilities Change -13.24 % 38.35 % -30.52 % 36.8 % 22.81 %
Seq. Cash & cash equivalent Change 22.93 % -16.47 % -12.68 % -5.52 % 40.97 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 250
Healthcare Sector # 419
Overall Market # 813


Quick Ratio Statistics
High Average Low
26.96 12.1 2.22
(Mar 31 2018)   (Mar 31 2017)




Financial Statements
Albireo Pharma Inc 's Current Liabilities $ 38 Millions Visit ALBO's Balance sheet
Albireo Pharma Inc 's Cash & cash equivalent $ 222 Millions Visit ALBO's Balance sheet
Source of ALBO's Sales Visit ALBO's Sales by Geography


Cumulative Albireo Pharma Inc 's Quick Ratio

ALBO's Quick Ratio for the trailling 12 Months

ALBO Quick Ratio

 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 47.04 % 60.47 % 59.41 % 61.9 % 63.28 %
Y / Y Cash & cash equivalent TTM Growth -5.35 % -2.68 % 1.62 % 9.8 % 26.71 %
Quick Ratio TTM 5.49 5.91 6.67 7.16 8.52
Total Ranking TTM # 4173 # 697 # 662 # 567 # 4026
Seq. Current Liabilities TTM Growth 3.04 % 12.12 % 7.28 % 18.64 % 12.45 %
Seq. Cash & cash equivalent TTM Growth -4.42 % -0.58 % -0.05 % -0.35 % -1.72 %

Quick ratio ranking by company, industry and sector >> Back to ALBO Financial Strength Comparisons >> Go to Compare ALBO Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q3 2022 to $37.82 millions, cumulative Quick Ratio decreased to 5.49 below the Albireo Pharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 553 other companies have achieved higher Quick Ratio than Albireo Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 697 to 4173.

Explain Quick Ratio?
How much Cash & cash equivalents ALBO´s has?
What are ALBO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 554
Healthcare Sector # 1108
Within the Market # 4173


trailing twelve months Quick Ratio Statistics
High Average Low
19.3 11.08 4.58
(Dec 31 2018)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Rapt Therapeutics Inc   15.87 $ 195.436  Millions$ 12.316  Millions
Fulcrum Therapeutics Inc   15.09 $ 221.789  Millions$ 14.699  Millions
Crinetics Pharmaceuticals Inc   15.00 $ 368.362  Millions$ 24.556  Millions
Nkarta Inc   14.85 $ 392.356  Millions$ 26.425  Millions
Akero Therapeutics Inc   14.82 $ 374.003  Millions$ 25.243  Millions
Pds Biotechnology Corp  14.80 $ 71.642  Millions$ 4.841  Millions
Protagenic Therapeutics Inc new  14.73 $ 8.153  Millions$ 0.554  Millions
Oric Pharmaceuticals Inc   14.58 $ 193.659  Millions$ 13.284  Millions
Cytokinetics Incorporated  14.36 $ 867.664  Millions$ 60.440  Millions
Cryoport inc   14.31 $ 530.451  Millions$ 37.076  Millions
Lianbio  14.15 $ 311.728  Millions$ 22.027  Millions
Gyre Therapeutics Inc   14.05 $ 23.090  Millions$ 1.644  Millions
Sage Therapeutics Inc   13.98 $ 1,393.639  Millions$ 99.687  Millions
Pliant Therapeutics Inc   13.77 $ 360.241  Millions$ 26.161  Millions
Sensei Biotherapeutics Inc   13.73 $ 116.558  Millions$ 8.492  Millions
Rani Therapeutics Holdings Inc   13.66 $ 98.171  Millions$ 7.186  Millions
Lumos Pharma Inc   13.44 $ 73.666  Millions$ 5.483  Millions
Annexon Inc   13.33 $ 269.519  Millions$ 20.220  Millions
Larimar Therapeutics Inc   13.24 $ 124.699  Millions$ 9.420  Millions
Liquidia Corporation  13.18 $ 98.320  Millions$ 7.460  Millions
Xenetic Biosciences Inc   13.18 $ 13.848  Millions$ 1.051  Millions
Psyence Biomedical ltd   13.05 $ 0.605  Millions$ 0.046  Millions
Aclaris Therapeutics Inc   13.04 $ 248.062  Millions$ 19.023  Millions
Iveric Bio Inc   13.04 $ 320.535  Millions$ 24.588  Millions
Erasca Inc   12.86 $ 355.928  Millions$ 27.679  Millions
Arcutis Biotherapeutics Inc   12.86 $ 476.963  Millions$ 37.102  Millions
Kronos Bio Inc   12.85 $ 258.255  Millions$ 20.105  Millions
Verrica Pharmaceuticals Inc   12.82 $ 39.454  Millions$ 3.078  Millions
Lyell Immunopharma Inc   12.65 $ 648.132  Millions$ 51.217  Millions
Pepgen Inc   12.62 $ 195.783  Millions$ 15.519  Millions

Date modified: 2026-09-08T15:10:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.